De Novo Hepatitis B
De Novo Hepatitis B - Related Videos
11:29
Reusable Hepatic Imaging Tool: A Reusable 3D-Printed Tool for Hepatic Intravital Microscopy
0 Views •
2026
This protocol introduces a cutting-edge, Reusable Hepatic Imaging Tool (RHIT) for intravital microscopy (IVM) of live mice, which enhances tissue stability for rapid and acute experiments. The RHIT's 3D-printed design offers cost-effective production, scalability, and versatility, enabling prolonged observation of metabolic processes in mice of various sizes.
05:51
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
0 Views •
Cited by 11 •
2011
Molecular genetic strategy for finding de novo mutations causing common disorders such as autism and schizophrenia.
10:41
Leveraging CyVerse Resources for De Novo Comparative Transcriptomics of Underserved (Non-model) Organisms
0 Views •
Cited by 7 •
2017
This protocol outlines a comparative de novo transcriptome assembly and annotation workflow for novice bioinformaticians. The workflow is available for free entirely through CyVerse and connected by the Data Store. Command line and graphical user interfaces are used, but all code needed is available to copy and paste.
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
0 Views •
Cited by 2 •
2017
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput strategy.
06:00
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
0 Views •
2025
We present a laparoscopic technique for anatomic S7+S8d resection with right hepatic vein transection, preserving the inferior right hepatic vein and segment S6. Relying on meticulous anatomical landmarks without intraoperative ultrasound, this approach offers a precise and parenchyma-sparing option for dorsally located right-liver tumors, particularly in settings with limited advanced navigation resources.
FAQs
Immunosuppressive therapy weakens the recipient’s immune control of HBV, allowing viral replication to increase rather than being adequately restrained. In a liver transplant recipient, that expansion can intensify liver injury and threaten graft function. This mechanism explains why infection may become clinically important after transplantation even when the recipient had no previously recognized HBV infection.
An HBV-infected donor graft can introduce the virus directly into a recipient, but donor assessment has an important limitation. Occult donor infection may escape routine hepatitis B surface-antigen testing, so a negative result does not eliminate every transmission pathway described for de novo hepatitis B. Recognizing this possibility supports careful recipient surveillance and prevention planning.
Because HBV replication can accelerate during immunosuppression, the consequences may extend from viral infection to injury of the transplanted liver. Clinicians therefore must consider both virologic control and preservation of graft function. This broader perspective explains why de novo hepatitis B management combines prevention, surveillance, and antiviral measures instead of treating transmission as a single isolated event.
Prevention begins with donor screening and continues with recipient monitoring after transplantation. Screening can identify recognized HBV infection before a graft is used, while follow-up helps detect infection that may not have been predicted, including infection linked to occult donor infection. This sequence connects donor risk assessment with early recognition in the recipient.
Antiviral prophylaxis with nucleos(t)ide analogues is a key strategy for reducing HBV transmission and subsequent viral persistence. Hepatitis B immunoglobulin may also be used when indicated, providing another preventive option within the management plan. Together, these measures support protection against chronic infection, graft dysfunction, and related complications in at-risk transplant recipients.
Recognizing de novo hepatitis B has practical value beyond identifying the virus. It prompts coordinated donor screening, post-transplant recipient monitoring, and preventive antiviral management. In medicine, these actions are intended to reduce transmission, chronic infection, graft dysfunction, and related complications. The approach is especially important when routine surface-antigen testing may not reveal an occult donor infection.